Ultra-low-dose THC given before Alzheimer symptoms appeared reduced brain inflammation in mice, with different brain regions affected by sex

Monthly ultra-low-dose THC in an Alzheimer mouse model attenuated cognitive decline in both sexes, with males showing reduced hippocampal inflammation and females showing reduced prefrontal cortex inflammation.

Nitzan, Keren et al.·Biology of sex differences·2026·Preliminary EvidenceAnimal StudyAnimal Study
RTHC-08520Animal StudyPreliminary Evidence2026RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

ULD-THC attenuated AD-related cognitive decline in both sexes. Males showed reduced hippocampal inflammation; females showed reduced prefrontal cortex inflammation. Treatment was given monthly from 3 to 5 months of age, before significant pathology.

Key Numbers

Monthly ULD-THC from age 3-5 months. Testing at 6 months. Males: reduced hippocampal inflammation. Females: reduced PFC inflammation. Both sexes: attenuated cognitive decline.

How They Did This

Male and female 5xFAD mice received monthly ULD-THC injections from 3-5 months. Behavioral assessments at 6 months, followed by molecular analyses of hippocampal and PFC tissue.

Why This Research Matters

No treatment effectively prevents Alzheimer onset. Ultra-low-dose THC, given before symptoms, reduced neuroinflammation and slowed cognitive decline without the adverse effects of chronic THC use.

The Bigger Picture

If doses too low to produce psychoactive effects can still provide neuroprotection, it could open a new therapeutic category with minimal side effect concerns.

What This Study Doesn't Tell Us

Mouse model. Difficult to translate ULD-THC dosing to humans. Only tested as prevention, not treatment. Short treatment window.

Questions This Raises

  • ?What is the human-equivalent dose?
  • ?Would this work after pathology is established?
  • ?Why do sexes show protection in different brain regions?

Trust & Context

Key Stat:
Preventive ULD-THC attenuated cognitive decline with sex-specific inflammation reduction
Evidence Grade:
Well-designed preclinical study with sex-stratified analysis, but mouse model results require extensive human validation.
Study Age:
2026 publication
Original Title:
Sex-dependent effects of ultra-low-dose-THC preventive treatment on neuroinflammation and cognitive decline in 5xFAD mice.
Published In:
Biology of sex differences, 17(1), 20 (2026)
Database ID:
RTHC-08520

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

Could THC prevent Alzheimer disease?

This mouse study suggests ultra-low doses before symptoms may help, but this is far from proven in humans.

What makes this ultra-low-dose?

Doses designed to be too low for psychoactive effects while still activating neuroprotective pathways.

Read More on RethinkTHC

Cite This Study

RTHC-08520·https://rethinkthc.com/research/RTHC-08520

APA

Nitzan, Keren; Bentulila, Ziv; Bregman-Yemini, Noa; Ayalon, Niv; David, Dekel; Break, Emanuela; Sarne, Yossi; Doron, Ravid. (2026). Sex-dependent effects of ultra-low-dose-THC preventive treatment on neuroinflammation and cognitive decline in 5xFAD mice.. Biology of sex differences, 17(1), 20. https://doi.org/10.1186/s13293-025-00815-3

MLA

Nitzan, Keren, et al. "Sex-dependent effects of ultra-low-dose-THC preventive treatment on neuroinflammation and cognitive decline in 5xFAD mice.." Biology of sex differences, 2026. https://doi.org/10.1186/s13293-025-00815-3

RethinkTHC

RethinkTHC Research Database. "Sex-dependent effects of ultra-low-dose-THC preventive treat..." RTHC-08520. Retrieved from https://rethinkthc.com/research/nitzan-2026-sexdependent-effects-of-ultralowdosethc

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.